Therapeutic agent for ischemic diseases

Patent metadata

Field	Value
Publication number	US-10993972-B2
Application number	US-201615544565-A
Country	US
Kind code	B2
Filing date	Jan 18, 2016
Priority date	Jan 19, 2015
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

Provided are: a transformation plasmid for transforming anaerobes and enabling highly efficient and stable secretory expression of a target protein; a gene delivery carrier formed from said anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these. Also provided are: a novel secretory signal; a transformation plasmid including said secretory signal; a gene delivery carrier formed from anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these.

First claim

The invention claimed is:

1. A transformation plasmid for an anaerobic bacterium, wherein the transformation plasmid consists of the base sequence of pFGF110 (SEQ ID NO: 14) or pFGF111 (SEQ ID NO: 15).

2. A gene transport carrier comprising an anaerobic bacterium transformed with the transformation plasmid according to claim 1 .

3. The gene transport carrier according to claim 2 , wherein the anaerobic bacterium is a Bifidobacterium.

4. The gene transport carrier according to claim 3 , wherein the Bifidobacterium is a Bifidobacterium longum.

5. A pharmaceutical composition comprising the gene transport carrier according to claim 2 .

6. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition further comprises an agent for promoting colonization and growth of the gene transport carrier at the site of an ischemic disease.

7. The pharmaceutical composition according to claim 6 , wherein the agent for promoting colonization and growth is at least one type selected from the group consisting of maltose, lactulose, arabinose, xylose, galactose, glucose, lactose, melibiose, melezitose, and raffinose.

8. A method for treating an ischemic disease, the method comprising administering the gene transport carrier according to claim 2 .

9. The method according to claim 8 , wherein said administration is systemic administration.

Assignees

• Univ Shinshu
• Anaeropharma Science Inc

Inventors

• Wada Yuko
• Shimatani Yuko
• Yano Takashi
• Masaki Takeshi

Classifications

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• G01N2800/2871

  Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title

• G01N2333/50

  Fibroblast growth factors [FGF] · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• C12N15/746 Primary

  for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus) · CPC title